Protocol ID

Official Title

Principal Investigator

Lead CRC

Disease Site

Phase

MK3475-641

ClinicalTrials.gov #

NCT03834493

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Dr. Jigarkumar Parikh

Joanne Huff

Prostate Cancer

III

MK3475-921

ClinicalTrials.gov #

NCT03834506

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE921

Dr. Jigarkumar Parikh

Joanne Huff

Prostate Cancer

III

MK7339-010

ClinicalTrials.gov #

NCT03834519 

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Dr. Jigarkumar Parikh

Joanne Huff

Prostate Cancer

III